Advertisement

Myelodysplastic Syndrome: An Overview

  • Jasmita Dass
  • Jyoti Kotwal
Chapter

Abstract

Myelodysplastic syndrome (MDS) is clonal hematopoietic stem cell disorders characterized by presence of cytopenia(s), dysplasia in ≥1 hematopoietic cell lineage, ineffective hematopoiesis, and an increased risk of progression to acute myeloid leukemia (AML) [1]. The diagnosis of MDS rests on the clinical features, presence of cytopenia in one or more myeloid lineages, morphological evidence of dysplasia, increased blasts in bone marrow and relevant cytogenetic abnormalities and molecular mutations. World Health organization (WHO) 2017 revised classification uses a combination of morphology, genetic features, and immunophenotype to assign a disease category to a case [2].

Keywords

Myelodysplastic syndrome WHO classification Diagnosis ICUS CHIP 

References

  1. 1.
    Cazzola M, Malcovati L. Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC; 2017.Google Scholar
  3. 3.
    Hamblin T. Clinical features of MDS. Leuk Res. 1992;16:89–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.PubMedCrossRefGoogle Scholar
  5. 5.
    Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of Tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.Google Scholar
  6. 6.
    Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.Google Scholar
  7. 7.
    Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.PubMedGoogle Scholar
  8. 8.
    Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007;21:668–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Parmentier S, Schetelig J, Lorenz K, Kramer M, Ireland R, Schuler U, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica. 2012;97(5):723–30.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Bain BJ, Clark DM, Wilkins B. Bone marrow pathology. 4th ed. Hoboken, NJ: Wiley-Blackwell; 2010.Google Scholar
  12. 12.
    Bain BJ. Leukaemia diagnosis. 4th ed. Hoboken, NJ: Wiley-Blackwell; 2010.CrossRefGoogle Scholar
  13. 13.
    Ramos F, Fernandez-Ferrero S, Suarez D, Barbon M, Rodriguez JA, Gil S, et al. Myelodysplastic syndrome: a search for minima diagnostic criteria. Leuk Res. 1999;23(3):283–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblast and ring sideroblasts. Haematologica. 2008;93:1712–7.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Arber DA, Hasserjian RP. Reclassifying myelodysplastic syndromes: what’s where in the new who and why. Hematol Am Soc Hematol Educ Prog. 2015;2015:294–8.CrossRefGoogle Scholar
  16. 16.
    Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–95.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012 Mar;26:542–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126(2):233–41.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113:3331–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.PubMedCrossRefGoogle Scholar
  22. 22.
    Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.PubMedCrossRefGoogle Scholar
  23. 23.
    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Jädersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica. 2009;94:1762–6.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Möllgård L, Saft L, Treppendahl MB, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 2011;96:963–71.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Gregg XT, Reddy V, Prchal JT. Copper deiciency masquerading as myelodysplastic syndrome. Blood. 2002;100:1493–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Fong T, Vij R, Vijayan A, et al. Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic syndrome. Haematologica. 2007;92:1429–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Halfdanarson TR, Kumar N, Li CY, et al. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol. 2008;80:523–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Monte SW, Sara AM, Michael LM, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123:125–31.CrossRefGoogle Scholar
  31. 31.
    Kar R, Rao S, Saxena R. Myelodysplastic syndromes: classification and prognostic scoring systems and their applicability in Indian scenario-experience from a tertiary care center. Hematology. 2009;14:145–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Braun T, Fenaux P. Myelodysplastic syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Pract Res Clin Haematol. 2013;26:327–36.PubMedCrossRefGoogle Scholar
  33. 33.
    Endi W, Elizabeth B, Imran S, et al. Pseudo–Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome–related Pseudo–Pelger-Huët anomaly. Am J Clin Pathol. 2011;135:291–303.CrossRefGoogle Scholar
  34. 34.
    Taegtmeyer AB, Halil O, Bell AD, et al. Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir. Transplantation. 2005;80:127–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Sharp RA, Lowe JG, Johnston RN. Anti-tuberculous drugs and sideroblastic anaemia. Br J Clin Pract. 1990;44:706–7.PubMedGoogle Scholar
  36. 36.
    Valent P, Orazzi A, Büschner G, et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget. 2010;1:483–96.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94:1066–74.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012;97:1209–17.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer. 2010;116:4549–63.PubMedCrossRefGoogle Scholar
  40. 40.
    Kern W, Bacher U, Haferlach C, et al. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplasti syndromes: a study on 804 patients. Cytometry B Clin Cytom. 2015;88:154–64.PubMedCrossRefGoogle Scholar
  41. 41.
    Wang SA, Pozdnyakova O, Jorgensen JL, et al. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica. 2009;94:29–37.PubMedCrossRefGoogle Scholar
  42. 42.
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias. French-American-british (FAB) co-operative group. Br J Haematol. 1976;33:451–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Wang SA, Patel KP, Pozdnyakova O, et al. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol. 2016;29:1221–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Calvo X, Arenillas L, Luno E, et al. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Mod Pathol. 2016;29:1541–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Santos FP, Faderl S, Garcia-Manero G, et al. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009;23(12):2275–80.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Bacher U, Haferlach C, Alpermann T, Kern W, Schnittger S, Haferlach T. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Haematologica. 2011;96(9):1284–92.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Hasserjian RP, Zuo Z, Garcia C, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010;115(10):1985–92.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Bacher U, Haferlach C, Alpermann T, et al. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Haematologica. 2011;96:1284–92.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658–70.PubMedCrossRefGoogle Scholar
  50. 50.
    Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia—a review. Br J Haematol. 2015;140:123–32.CrossRefGoogle Scholar
  51. 51.
    Nickels EM, Soodalter J, Churpek JE, et al. Recognizing familial myeloid leukemia in adults. Ther Adv Hematol. 2013;4:254–69.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci. 2014;1310:111–8.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Collin M, Dickinson R, Bigley V. Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol. 2015;169:173–87.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Hsu AP, McReynolds L, Holland SM. GATA2 deficiency. Curr Opin Allergy Clin Immunol. 2015;15:104–9.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Micol JB, Abdel-Wahab O. Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL 1 mutations in patients with germline GATA2 mutations. Haematologica. 2014;99:201–3.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127:1387–97.PubMedCrossRefGoogle Scholar
  57. 57.
    Calvo KR, Vinh DC, Marie I, et al. Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica. 2011;96:221–5.CrossRefGoogle Scholar
  58. 58.
    Churpek JE, Lorenz R, Nedumgottil S, et al. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma. 2013;54:28–35.PubMedCrossRefGoogle Scholar
  59. 59.
    Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–10.PubMedCrossRefGoogle Scholar
  60. 60.
    Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29:1502–13.PubMedCrossRefGoogle Scholar
  61. 61.
    Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538–43.PubMedCrossRefGoogle Scholar
  62. 62.
    Bowen KL, Davis BH. Abnormal patterns of expression of CD16 (FcR-III) and CD11b (CRIII) antigens by developing neutrophils in the bone marrow of patients with myelodysplastic syndrome. Lab Hematol. 1997;3:292–8.Google Scholar
  63. 63.
    Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98:979–87.PubMedCrossRefGoogle Scholar
  64. 64.
    Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730–41.PubMedCrossRefGoogle Scholar
  65. 65.
    Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014;28(9):1793–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691–8.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124:2793–803.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Bejar R, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705–12.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403–11.PubMedCrossRefGoogle Scholar
  74. 74.
    Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28:78–87.PubMedCrossRefGoogle Scholar
  75. 75.
    Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338–47.PubMedCrossRefGoogle Scholar
  76. 76.
    Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–87.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–98.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Kwok B, Hall JM, Witte JS, et al. MDS associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126(21):2355–61.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Valent P, Hprny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–36.PubMedCrossRefGoogle Scholar
  81. 81.
    Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jasmita Dass
    • 1
  • Jyoti Kotwal
    • 1
  1. 1.Department of HematologySir Ganga Ram HospitalNew DelhiIndia

Personalised recommendations